home / stock / srne / srne news

SRNE News and Press, Sorrento Therapeutics Inc. From 05/17/22

Stock Information
Company Name: Sorrento Therapeutics Inc.
Stock Symbol: SRNE
Market: NASDAQ
Website: sorrentotherapeutics.com
Menu
SRNE SRNE Quote SRNE Short SRNE News SRNE Articles SRNE Message Board
Get SRNE Alerts

News, Short Squeeze, Breakout and More Instantly...
SRNE - Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Socazolimab (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MAB TM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories. COF has completed the pati...
SRNE - Sorrento stock rises after FDA gives nod to begin phase 2 study of abivertinib to treat prostate cancer

Sorrento Therapeutics (NASDAQ:SRNE +5.6%) said on Tuesday it had received clearance from the FDA for its application to begin trial for a Phase 2 study of Abivertinib to be conducted in participants with metastatic castrate resistant prostate cancer ((mCRPC)) at multiple center...

SRNE - Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee(TM)) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

FDA granted IND clearance for Abivertinib (Fujovee™) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States. Abivertinib is a novel small molecule tyrosine kinase inh...

SRNE - Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination betwe

PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nas...
SRNE - Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia

SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There is a clear medical need for new, safe and effective treatments with the potential to improve care for the estimated 10 million FM p...

SRNE - Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA(TM)) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting

SP-102 (SEMDEXA TM ) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates. The study met its primary endpoint with a hig...

SRNE - Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients

A166 is a third-generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena Biopharma’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock™ conjugation chemistry. A166 has demonstrated promising antitumor a...
SRNE - Why Sorrento Therapeutics Stock Shot 7% Higher Today

A rising stock price is the cure for any investor's glum mood. Sorrento Therapeutics (NASDAQ: SRNE) provided a big dose of this on Monday; its shares gained over 7% thanks to encouraging news from the laboratory about the company's coronavirus drug candidate. That morning, Sorre...

SRNE - 3 Penny Stocks to Watch During the Stock Market Crash

Hot Penny Stocks For Your Watchlist as the Stock Market Falls Again While investing in penny stocks is never easy, doing so during a market crash is even more difficult. The key to success when it comes to buying penny stocks is to find the right stocks at the right time. To do this...

SRNE - Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD(TM) IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

The Phase I safety and pharmacokinetic study in 24 healthy volunteers has completed enrollment. The study is still blinded, but only 5 minor adverse events requiring no treatment have been reported in the entire study to date, similar to the safety profile observed in Sorrento’s CO...
Previous 10 Next 10